Observational Study for Left Main Disease Treatment
ConditionCoronary Artery Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSeung-Jung Park
About this trial
The purpose of this study is to observe clinical courses for long-term in patients with unprotected LMCA disease and to evaluate comparative results of medical treatment, coronary stenting with drug-eluting stents, and CABG for the treatment of an unprotected LMCA stenosis in the "real world" daily practice.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Significant unprotected left main stenosis (>50% by visual estimation)
The LMCA is considered unprotected if there are no patent coronary artery bypass grafts to the left anterior descending artery or the left circumflex artery.
No limitation of clinical or lesion characteristics
Age >18 years
Disqualifiers
Protected left main stenosis
Trial population
Consecutive patients with unprotected LMCA diseases at participating centers will be evaluated for the entry into the study.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
10,000 Participants
are grouped into 1 trial groupGroup A: Left Main disease
Trial outcomes
Primary outcomes
1
Composite event rate of death, myocardial infarction, Target Vessel Revascularization or cerebrovascular event
A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event that is considered to have occurred if any one of several different events is observed.
Time frame
2-yearSecondary outcomes
1
Death
Time frame
10-year2
Cardiac death
Time frame
10-year3
Myocardial infarction
Time frame
10-year4
Cerebrovascular event
Time frame
10-yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Seung-Jung Park
Lead sponsor
CardioVascular Research Foundation, Korea
Sponsor institution
CardioVascular Research Foundation, Korea
Collaborator
Source ClinicalTrials.gov